• 25-Hydroxycholesterol Activates Lysosomal AMPK in TAMs for I

  2026-06-19

  Xiao et al. (2024) identified a novel mechanism in which 25-hydroxycholesterol (25HC) accumulates within tumor-associated macrophages (TAMs), leading to lysosomal AMPKα activation via the GPR155-mTORC1 axis and subsequent immunosuppressive programming. Targeting this pathway reprograms macrophages, enhances anti-tumor T cell responses, and synergizes with anti-PD-1 therapy, suggesting new immunometabolic checkpoints for cancer intervention.

• Pepstatin A: Aspartic Protease Inhibitor for Advanced Assays

  2026-06-18

  Pepstatin A from APExBIO is a gold-standard aspartic protease inhibitor enabling precise control of viral protein processing and osteoclast differentiation workflows. This guide translates recent experimental breakthroughs into actionable protocols and troubleshooting insights, empowering researchers to maximize reproducibility and clarity in protease-targeted studies.

• N1-Methylpseudouridine: Redefining mRNA Translation for Dise

  2026-06-18

  This thought-leadership article explores the mechanistic advantages and translational strategies associated with N1-Methylpseudouridine, a modified nucleoside that is driving a paradigm shift in mRNA therapeutics. By critically synthesizing recent breakthrough findings on Niemann-Pick Disease Type C1 and integrating advanced workflow guidance, the piece provides actionable insights for translational researchers aiming to maximize protein expression while minimizing immunogenicity. The discussion goes beyond conventional product summaries, mapping a strategic trajectory for the next generation of mRNA-based disease modeling and therapy.

• Semi-Automated Screening of Fast-Dissociating Antibodies for

  2026-06-17

  Miyoshi et al. introduce a semi-automated single-molecule microscopy method to screen fast-dissociating, highly specific antibodies directly from hybridoma cultures. This approach enables the identification and generation of monoclonal antibodies suitable for advanced imaging of epitope-tagged proteins, with direct implications for multiplexed protein detection and dynamic studies in cell biology.

• Human Milk L. reuteri FN041 Reduces Colitis via Microbiota M

  2026-06-17

  This study demonstrates that Limosilactobacillus reuteri FN041, isolated from human milk, alleviates DSS-induced colitis in mice by restoring gut microbiota diversity and key metabolites. The findings highlight a promising probiotic intervention for ulcerative colitis, supported by comprehensive metagenomic and metabolomic analyses.

• Canagliflozin: Mitochondrial Remodeling and Renal Bioenerget

  2026-06-16

  Explore how Canagliflozin, a potent SGLT2 inhibitor, redefines diabetes and kidney disease research by driving mitochondrial remodeling and enhancing renal bioenergetics. This article uniquely integrates mechanistic insights, translational implications, and protocol guidance for metabolic disease models.

• A40926: Mechanistic Insights and Strategic Leverage in Trans

  2026-06-16

  This thought-leadership article explores the mechanistic underpinnings of A40926, the dalbavancin precursor, and its pivotal role in translational research against Gram-positive and multidrug-resistant bacteria. Integrating recent advances in biosynthetic optimization, assay design, and clinical translation, it provides actionable guidance for researchers seeking to harness A40926 within innovative antibiotic discovery and resistance management workflows. Building on the latest peer-reviewed evidence and scenario-driven resources, the article contextualizes A40926’s impact beyond conventional product overviews, offering a roadmap for scientific progress and strategic differentiation.

• Efficient Purification of Recombinant Annexin V for Biophysi

  2026-06-15

  This study introduces a rapid and highly effective protocol for purifying recombinant annexin V, facilitating advanced biophysical investigations. By leveraging calcium-mediated binding and mild cell lysis, the method yields exceptionally pure protein for structural and functional studies, informing both mechanistic understanding and practical workflows.

• Neuromedin S (rat): Technical Workflow and Protocol Guidance

  2026-06-15

  Neuromedin S (rat) provides a chemically defined, endogenous agonist for precise activation of neuromedin U receptor signaling in rat-based GPCR/G protein assays. It addresses the need for standardized, reproducible ligand input in workflows investigating energy homeostasis, stress response, and circadian regulation. This reagent is intended strictly for controlled laboratory research applications and is not suitable for diagnostic or therapeutic use.

• Applied Workflows with the Alcian Blue & Nuclear Fast Red St

  2026-06-14

  Unlock precise chondrogenic and mucopolysaccharide analysis with the Alcian Blue & Nuclear Fast Red Staining Kit, pH2.5. This guide delivers expert-driven protocols, troubleshooting insights, and translational best practices for stem cell and tissue histology workflows.

• XXLP Modulates NOX2/ROS/Mitochondria/NLRP3 Axis in Colitis M

  2026-06-13

  Xu Chunfu’s Modified Xianglian Pill (XXLP) demonstrates a targeted anti-inflammatory effect in ulcerative colitis by suppressing the NOX2/ROS/mitochondria/NLRP3 axis and remodeling gut microbiota. This study establishes mechanistic insights into XXLP’s action and suggests new strategies for integrative colitis therapy.

• Fractional Viability Metrics Advance In Vitro Cancer Drug As

  2026-06-12

  Schwartz's dissertation introduces a refined approach to evaluating anti-cancer drug responses by distinguishing between growth inhibition and cell death using fractional viability metrics. This innovation improves the accuracy of in vitro drug testing, with practical implications for research on agents like Bleomycin Sulfate and for studies in pulmonary fibrosis and cancer biology.

• BML-277: Precision Chk2 Inhibitor for DNA Damage Response Re

  2026-06-12

  BML-277 enables robust, ATP-competitive Chk2 inhibition with nanomolar potency, empowering advanced studies on radioprotection of T-cells and cGAS-mediated genome defense. Its stability, selectivity, and actionable protocol parameters make it a premier choice for dissecting DNA damage pathways in cancer and genome integrity research.

• Lumiracoxib (SKU B1458): Reliable COX-2 Inhibition for Cell

  2026-06-11

  This article explores practical laboratory challenges in COX-2 pathway research and demonstrates how Lumiracoxib (SKU B1458) delivers reproducible, data-driven solutions for cell viability and inflammation assays. Drawing on recent peer-reviewed evidence and APExBIO's product specifications, we detail protocol optimization, data interpretation, and vendor selection strategies for robust experimental outcomes.

• Methyl-β-cyclodextrin: Technical Use in Membrane Cholesterol

  2026-06-11

  Methyl-β-cyclodextrin is a high-purity biochemical reagent designed for efficient extraction of cholesterol and certain lipids from cell membranes, supporting studies of membrane fluidity and lipid raft organization. It is not suitable for diagnostic or therapeutic applications; precision in handling and workflow setup is essential for reproducible research outcomes.

450 records 14/30 page Previous Next First page 上5页 1112131415 下5页 Last page